Archives of Endocrinology and Metabolism

Archives of Endocrinology and Metabolism

WoS IF 2024 - 2.3
Scimago SJR - 0.429
h5 Index - 26 Qualis - B2
How to submit your article?
Submit
  • About
    About the Journal Cookies Policy
  • Editorial Board
  • Available Issues
  • Instructions for Authors

Archives of Endocrinology and Metabolism

  • About
    • About the Journal
    • Cookies Policy
  • Editorial Board
  • Available Issues
  • Instructions for Authors
  1. Home
  2. Available Issues
  3. Table of Contents

Volume 66, Number 5, 2022

  • Previous
  • Next

EDITORIAL

Bone diseases and the COVID-19 pandemic

Francisco
Bandeira ORCID logo
,
John P.
Bilezikian ORCID logo

343
Bone diseases and the COVID-19 pandemic

November/2022

Bone diseases and the COVID-19 pandemic

Francisco
Bandeira ORCID logo
,
John P.
Bilezikian ORCID logo

DOI: 10.20945/2359-3997000000548

Although much has been learned about the acute consequences of SARS-CoV-2 infection, the chronic impact on human health is still largely unknown (). In addition to respiratory symptoms, general features such as fatigue, myalgias and joint pain may persist, usually associated with low-grade inflammation (). Acute SARS-CoV-2 infection in its moderate to severe form can lead to a high mortality rate especially in vulnerable individuals such as the elderly, a subgroup of patients in whom common muscle-skeletal disorders frequently occur. […]

343
More

consensus

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)

Barbara C.
Silva ORCID logo
,
Miguel
Madeira ORCID logo
,
Catarina Brasil
d’Alva ORCID logo
,
Sergio Setsuo
Maeda ORCID logo
,
Narriane Chaves Pereira de
Holanda ORCID logo
,
[...], Francisco
Bandeira ORCID logo

1,806
Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)

October/2022

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)

Barbara C.
Silva ORCID logo
,
Miguel
Madeira ORCID logo
,
Catarina Brasil
d’Alva ORCID logo
,
Sergio Setsuo
Maeda ORCID logo
,
Narriane Chaves Pereira de
Holanda ORCID logo
,
[...], Francisco
Bandeira ORCID logo

DOI: 10.20945/2359-3997000000522

ABSTRACT Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are […]

Keywords: anabolic; Osteoporosis; romosozumab; Teriparatide; very high risk of fracture

1,806
More

Guideline

Hypoparathyroidism: update of guidelines from the 2022 International Task Force

Bart L.
Clarke ORCID logo

1,490
Hypoparathyroidism: update of guidelines from the 2022 International Task Force

November/2022

Hypoparathyroidism: update of guidelines from the 2022 International Task Force

Bart L.
Clarke ORCID logo

DOI: 10.20945/2359-3997000000549

ABSTRACT The 2022 International Task Force guidelines for chronic hypoparathyroidism will be published within several months in the Journal of Bone and Mineral Research. These guidelines update the original guidelines published in 2016, and include new information from literature published since then. Chronic postsurgical hypoparathyroidism is now defined as lasting for at least 12 months after surgery, rather than 6 months. Chronic postsurgical hypoparathyroidism may be predicted by serum PTH

Keywords: hypocalcemia; Hypoparathyroidism; increased bone density; nephrocalcinosis; Nephrolithiasis

1,490
More

Review

Bone, fat, and muscle interactions in health and disease

Mayra Macena
Gomes ORCID logo
,
Maisa Monseff Rodrigues da
Silva ORCID logo
,
Iana Mizumukai de
Araújo ORCID logo
,
Francisco José Albuquerque de
Paula ORCID logo

437
Bone, fat, and muscle interactions in health and disease

Bone, fat, and muscle interactions in health and disease

Mayra Macena
Gomes ORCID logo
,
Maisa Monseff Rodrigues da
Silva ORCID logo
,
Iana Mizumukai de
Araújo ORCID logo
,
Francisco José Albuquerque de
Paula ORCID logo

DOI: 10.20945/2359-3997000000550

Abstract Energy metabolism is a point of integration among the various organs and tissues of the human body, not only in terms of consumption of energy substrates but also because it concentrates a wide interconnected network controlled by endocrine factors. Thus, not only do tissues consume substrates, but they also participate in modulating energy metabolism. Soft mesenchymal tissues, in particular, play a key role in this process. The recognition that high energy consumption is involved in bone remodeling has been […]

Keywords: diabetes mellitus; energy metabolism; mineral metabolism; obesity; Osteoporosis

437
More

Musculoskeletal effects of obesity and bariatric surgery – a narrative review

Narriane
Holanda ORCID logo
,
Nara
Crispim ORCID logo
,
Ingrid
Carlos ORCID logo
,
Taíssa
Moura ORCID logo
,
Eduardo
Nóbrega ORCID logo
,
Francisco
Bandeira ORCID logo

524
Musculoskeletal effects of obesity and bariatric surgery – a narrative review

Musculoskeletal effects of obesity and bariatric surgery – a narrative review

Narriane
Holanda ORCID logo
,
Nara
Crispim ORCID logo
,
Ingrid
Carlos ORCID logo
,
Taíssa
Moura ORCID logo
,
Eduardo
Nóbrega ORCID logo
,
Francisco
Bandeira ORCID logo

DOI: 10.20945/2359-3997000000551

Abstract Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies, […]

Keywords: Bariatric surgery; Bone; obesity; sarcopenia

524
More

Diabetes and bone

Iana Mizumukai de
Araújo ORCID logo
,
Mariana Lima Mascarenhas
Moreira ORCID logo
,
Francisco José Albuquerque de
Paula ORCID logo

679
Diabetes and bone

Diabetes and bone

Iana Mizumukai de
Araújo ORCID logo
,
Mariana Lima Mascarenhas
Moreira ORCID logo
,
Francisco José Albuquerque de
Paula ORCID logo

DOI: 10.20945/2359-3997000000552

Abstract Globally, one in 11 adults has diabetes mellitus of which 90% have type 2 diabetes. The numbers for osteoporosis are no less staggering: 1 in 3 women has a fracture after menopause, and the same is true for 1 in 5 men after the age of 50 years. Aging is associated with several physiological changes that cause insulin resistance and impaired insulin secretion, which in turn lead to hyperglycemia. The negative balance between bone resorption and formation is a […]

Keywords: diagnosis; fracture; FRAX; glucose; insulin

679
More

Skeletal and nonskeletal consequences of hypoparathyroidism

Barbara C.
Silva ORCID logo

462
Skeletal and nonskeletal consequences of hypoparathyroidism

Skeletal and nonskeletal consequences of hypoparathyroidism

Barbara C.
Silva ORCID logo

DOI: 10.20945/2359-3997000000553

ABSTRACT Hypoparathyroidism, despite the conventional therapy with calcium and active vitamin D, can lead to skeletal and nonskeletal abnormalities. Chronic hypoparathyroidism is associated with a significant reduction in bone remodeling, increases in areal and volumetric bone density, and improvement in trabecular microarchitecture and in trabecular bone score. Regardless of these advantages in bone mass and microarchitecture, recent data suggest an increased vertebral fracture risk in patients with nonsurgical hypoparathyroidism. Moreover, chronic hypoparathyroidism can lead to abnormalities in multiple organ systems, […]

Keywords: cataract; fracture risk; Hypoparathyroidism; Nephrolithiasis; quality of life

462
More

Treatment options in hypoparathyroidism

Eliane Naomi
Sakane ORCID logo
,
Maria Carolina Camargo
Vieira ORCID logo
,
Gabriela Mazzarolo Marcondes
Vieira ORCID logo
,
Sergio Setsuo
Maeda ORCID logo

726
Treatment options in hypoparathyroidism

Treatment options in hypoparathyroidism

Eliane Naomi
Sakane ORCID logo
,
Maria Carolina Camargo
Vieira ORCID logo
,
Gabriela Mazzarolo Marcondes
Vieira ORCID logo
,
Sergio Setsuo
Maeda ORCID logo

DOI: 10.20945/2359-3997000000554

ABSTRACT Hypoparathyroidism remains the single endocrine deficiency disease that is not habitually treated with the missing hormone. In this article, we aim to provide a review of the conventional approach and the novel therapies as well as an overview of the perspectives on the treatment of this rare condition. We conducted a literature review on the conventional therapy using vitamin D analogs and calcium salts, indications for thiazide diuretics and phosphorus binders, PTH analogs history and usage, and the drugs […]

Keywords: Hypoparathyroidism; Perspectives; PTH analogs; treatment; Vitamin D

726
More

New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia

Julia Vieira Oberger
Marques ORCID logo
,
Carolina Aguiar
Moreira ORCID logo
,
Victoria Zeghbi Cochenski
Borba ORCID logo

545
New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia

New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia

Julia Vieira Oberger
Marques ORCID logo
,
Carolina Aguiar
Moreira ORCID logo
,
Victoria Zeghbi Cochenski
Borba ORCID logo

DOI: 10.20945/2359-3997000000555

Abstract Phosphorus is one of the most abundant minerals in the human body; it is required to maintain bone integrity and mineralization, in addition to other biological processes. Phosphorus is regulated by parathyroid hormone, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], and fibroblast growth factor 23 (FGF-23) in a complex set of processes that occur in the gut, skeleton, and kidneys. Different molecular mechanisms – overproduction of FGF-23 by tumors responsible for oncogenic osteomalacia, generation of an FGF-23 mutant that is resistant to cleavage […]

Keywords: burosumab; FGF-23; hypophosphatemia; Osteomalácia; Rickets

545
More

Normocalcemic primary hyperparathyroidism

Natalie E.
Cusano ORCID logo
,
Filomena
Cetani ORCID logo

1,194
Normocalcemic primary hyperparathyroidism

Normocalcemic primary hyperparathyroidism

Natalie E.
Cusano ORCID logo
,
Filomena
Cetani ORCID logo

DOI: 10.20945/2359-3997000000556

ABSTRACT Normocalcemic primary hyperparathyroidism (PHPT) is a newer phenotype of PHPT defined by elevated PTH concentrations in the setting of normal serum calcium levels. It is increasingly being diagnosed in the setting of evaluation for nephrolithiasis or metabolic bone diseases. It is important to demonstrate that PTH values remain consistently elevated and to measure ionized calcium levels to make the diagnosis. A diagnosis of normocalcemic disease is one of exclusion of secondary forms of hyperparathyroidism, including vitamin D deficiency, renal […]

Keywords: calcium; Hyperparathyroidism; Nephrolithiasis; Osteoporosis; parathyroid hormone; parathyroid surgery

1,194
More

Surgery for primary hyperparathyroidism

Murilo Catafesta das
Neves ORCID logo
,
Rodrigo Oliveira
Santos ORCID logo
,
Monique Nakayama
Ohe ORCID logo

486
Surgery for primary hyperparathyroidism

Surgery for primary hyperparathyroidism

Murilo Catafesta das
Neves ORCID logo
,
Rodrigo Oliveira
Santos ORCID logo
,
Monique Nakayama
Ohe ORCID logo

DOI: 10.20945/2359-3997000000557

ABSTRACT Primary hyperparathyroidism (PHPT) is a hypercalcemic disorder that occurs when one or more parathyroid glands produces excessive parathyroid hormone (PTH). PHPT is typically treated with surgery, and it remains the only definitive therapy, whose techniques have evolved over previous decades. Advances in preoperative localization exams and the intraoperative PTH monitoring have become the cornerstones of recent parathyroidectomy techniques, as minimally invasive techniques are appropriate for most patients. Nevertheless, these techniques, are not suitable for PHPT patients who are at […]

Keywords: parathyroid hormone; parathyroidectomy; Primary hyperparathyroidism; treatment

486
More

Medical management of primary hyperparathyroidism

Francisco
Bandeira ORCID logo
,
Janiere de Moura
Nóbrega ORCID logo
,
Lucian Batista de
Oliveira ORCID logo
,
John
Bilezikian ORCID logo

966
Medical management of primary hyperparathyroidism

Medical management of primary hyperparathyroidism

Francisco
Bandeira ORCID logo
,
Janiere de Moura
Nóbrega ORCID logo
,
Lucian Batista de
Oliveira ORCID logo
,
John
Bilezikian ORCID logo

DOI: 10.20945/2359-3997000000558

ABSTRACT Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used […]

Keywords: conservative therapies; Hypercalcemia; parathyroid hormone; Primary hyperparathyroidism

966
More

Update on trabecular bone score

Telma
Palomo ORCID logo
,
Patricia
Muszkat ORCID logo
,
Fernanda G.
Weiler ORCID logo
,
Patricia
Dreyer ORCID logo
,
Cynthia M. A.
Brandão ORCID logo
,
Barbara C.
Silva ORCID logo

1,591
Update on trabecular bone score

Update on trabecular bone score

Telma
Palomo ORCID logo
,
Patricia
Muszkat ORCID logo
,
Fernanda G.
Weiler ORCID logo
,
Patricia
Dreyer ORCID logo
,
Cynthia M. A.
Brandão ORCID logo
,
Barbara C.
Silva ORCID logo

DOI: 10.20945/2359-3997000000559

ABSTRACT Trabecular bone score (TBS) is an indirect and noninvasive measure of bone quality. A low TBS indicates degraded bone microarchitecture, predicts osteoporotic fracture, and is partially independent of clinical risk factors and bone mineral density (BMD). There is substantial evidence supporting the use of TBS to assess vertebral, hip, and major osteoporotic fracture risk in postmenopausal women, as well as to assess hip and major osteoporotic fracture risk in men aged > 50 years. TBS complements BMD information and […]

Keywords: dual-energy x-ray absorptiometry; fracture risk; Osteoporosis; Secondary osteoporosis; Trabecular bone score

1,591
More

Anabolic therapy for osteoporosis: update on efficacy and safety

Leonardo
Bandeira ORCID logo
,
E. Michael
Lewiecki ORCID logo

1,133
Anabolic therapy for osteoporosis: update on efficacy and safety

Anabolic therapy for osteoporosis: update on efficacy and safety

Leonardo
Bandeira ORCID logo
,
E. Michael
Lewiecki ORCID logo

DOI: 10.20945/2359-3997000000566

ABSTRACT Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that increase bone remodeling with bone formation increasing more than bone resorption. Romosozumab is a humanized monoclonal antibody to sclerostin that has a “dual effect” of increasing bone formation while decreasing bone resorption. The bone forming effects of anabolic therapy […]

Keywords: abaloparatide; Osteoporosis; romosozumab; Teriparatide; treatment

1,133
More

Long-term consequences of osteoporosis therapy with denosumab

Francisco
Bandeira ORCID logo
,
Lucian Batista de
Oliveira ORCID logo
,
John P.
Bilezikian ORCID logo

591
Long-term consequences of osteoporosis therapy with denosumab

Long-term consequences of osteoporosis therapy with denosumab

Francisco
Bandeira ORCID logo
,
Lucian Batista de
Oliveira ORCID logo
,
John P.
Bilezikian ORCID logo

DOI: 10.20945/2359-3997000000560

ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb continued on drug, while those who were randomized to placebo transitioned to DMAb. The 10-year experience with DMAb provides data on […]

Keywords: bone remodeling; Denosumab; fractures; osteonecrosis; Osteoporosis

591
More

The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence

Manju
Chandran ORCID logo

1,285
The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence

The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence

Manju
Chandran ORCID logo

DOI: 10.20945/2359-3997000000564

ABSTRACT It is now well recognized that over the lifetime of a patient with osteoporosis, more than one medication will be needed to treat the disease and to decrease fracture risk. Though current gaps in osteoporosis therapy can be potentially mitigated with sequential and combination regimens, how to move seamlessly amongst the multiple treatments currently available for osteoporosis for sustained efficacy is still unclear. Data from recent studies show that an anabolic agent such as teriparatide or romosozumab followed by […]

Keywords: anabolic; antiresorptives; combination; drug holiday; imminent fracture risk; Osteoporosis; sequence; Sequential

1,285
More

Male osteoporosis

Leonardo
Bandeira ORCID logo
,
Barbara C.
Silva ORCID logo
,
John P.
Bilezikian ORCID logo

903
Male osteoporosis

Male osteoporosis

Leonardo
Bandeira ORCID logo
,
Barbara C.
Silva ORCID logo
,
John P.
Bilezikian ORCID logo

DOI: 10.20945/2359-3997000000563

ABSTRACT Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population. Despite these facts, only 10% of men with osteoporosis […]

Keywords: hypogonadism; male; Osteoporosis; testosterone

903
More

Vitamin D metabolism and extraskeletal outcomes: an update

Isabela Cristina Januário
Silva ORCID logo
,
Marise
Lazaretti-Castro ORCID logo

765
Vitamin D metabolism and extraskeletal outcomes: an update

Vitamin D metabolism and extraskeletal outcomes: an update

Isabela Cristina Januário
Silva ORCID logo
,
Marise
Lazaretti-Castro ORCID logo

DOI: 10.20945/2359-3997000000565

ABSTRACT Vitamin D deficiency is a general health problem affecting individuals at all stages of life and on different continents. The musculoskeletal effects of vitamin D are well known. Its deficiency causes rickets, osteomalacia, and secondary hyperparathyroidism and increases the risk of fractures. Clinical and experimental evidence suggests that vitamin D performs multiple extraskeletal functions. Several tissues unrelated to calcium and phosphate metabolism express vitamin D receptor (VDR) and are directly or indirectly influenced by 1,25(OH)2D (calcitriol). Some also express […]

Keywords: randomized controlled trial; Vitamin D; vitamin D metabolism; vitamin D/physiology; vitamin D/therapeutic use

765
More

Celiac disease and bone

Ananya V.
Kondapalli ORCID logo
,
Marcella Donovan
Walker ORCID logo

641
Celiac disease and bone

Celiac disease and bone

Ananya V.
Kondapalli ORCID logo
,
Marcella Donovan
Walker ORCID logo

DOI: 10.20945/2359-3997000000561

Abstract Celiac disease (CD) is an autoimmune disorder characterized by small intestinal inflammation triggered by gluten ingestion in genetically-predisposed individuals. A frequent extra-intestinal manifestation of CD is metabolic bone disease which contributes to an increased risk of fracture. The mechanisms underlying bone disease in CD remain incompletely understood, but multiple processes have been proposed including (1) malabsorption of calcium and vitamin D leading to secondary hyperparathyroidism and increased skeletal resorption, (2) pro-inflammatory cytokines altering the osteoprotegerin and receptor activator of […]

Keywords: bone density; fracture; gluten; inflammation; microarchitecture

641
More

Stress fractures

Tatiana Munhoz da Rocha lemos
Costa ORCID logo
,
Victoria Zeghbi Cochenski
Borba ORCID logo
,
Renata Gonçalves Pinheiro
Correa ORCID logo
,
Carolina Aguiar
Moreira ORCID logo

1,137
Stress fractures

Stress fractures

Tatiana Munhoz da Rocha lemos
Costa ORCID logo
,
Victoria Zeghbi Cochenski
Borba ORCID logo
,
Renata Gonçalves Pinheiro
Correa ORCID logo
,
Carolina Aguiar
Moreira ORCID logo

DOI: 10.20945/2359-3997000000562

ABSTRACT Stress fractures (SF) represent 10%-20% of all injuries in sport medicine. An SF occurs when abnormal and repetitive loading is applied on normal bone: The body cannot adapt quickly enough, leading to microdamage and fracture. The etiology is multifactorial with numerous risk factors involved. Diagnosis of SF can be achieved by identifying intrinsic and extrinsic factors, obtaining a good history, performing a physical exam, and ordering laboratory and imaging studies (magnetic resonance imaging is the current gold standard). Relative […]

Keywords: athlete triad; magnetic resonance; Overtraining; RED syndrome; Stress fractures

1,137
More

Search

Keywords

diabetes mellitus - 267 obesity - 222 insulin resistance - 117 metabolic syndrome - 109 Osteoporosis - 95 diabetes - 93 Thyroid cancer - 76 tratamento - 72 Type 1 diabetes - 64 treatment - 62 hypothyroidism - 62 resistência à insulina - 61 Growth hormone - 59 thyroid - 54 Type 1 diabetes mellitus - 54 Acromegaly - 52 hypertension - 47 type 2 diabetes mellitus - 44 Hyperthyroidism - 44 cancer - 41
Archives of Endocrinology and Metabolism

Rua Botucatu, 572 – conjuntos 81/83
Vila Clementino – São Paulo / SP
Zip Code: 04023-062
Phones: +55 (11) 5575-0311 / +55 (11) 99768-6933
E-mail: aem.editorial.office@endocrino.org.br

  • About
    • About the Journal
    • Cookies Policy
  • Editorial Board
  • Available Issues
  • Instructions for Authors
  • About
    • About the Journal
    • Cookies Policy
  • Editorial Board
  • Available Issues
  • Instructions for Authors
AEM SBEM

Santana Serviços Editoriais
Developed by
CABOVERDE
Gerenciar Consentimento de Cookies
We use cookies to optimize our website and our service.
Functional Always active
O armazenamento ou acesso técnico é estritamente necessário para a finalidade legítima de permitir a utilização de um serviço específico explicitamente solicitado pelo assinante ou utilizador, ou com a finalidade exclusiva de efetuar a transmissão de uma comunicação através de uma rede de comunicações eletrónicas.
Preferences
O armazenamento ou acesso técnico é necessário para o propósito legítimo de armazenar preferências que não são solicitadas pelo assinante ou usuário.
Estatísticas
O armazenamento ou acesso técnico que é usado exclusivamente para fins estatísticos. O armazenamento técnico ou acesso que é usado exclusivamente para fins estatísticos anônimos. Sem uma intimação, conformidade voluntária por parte de seu provedor de serviços de Internet ou registros adicionais de terceiros, as informações armazenadas ou recuperadas apenas para esse fim geralmente não podem ser usadas para identificá-lo.
Marketing
O armazenamento ou acesso técnico é necessário para criar perfis de usuário para enviar publicidade ou para rastrear o usuário em um site ou em vários sites para fins de marketing semelhantes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
Preferences
{title} {title} {title}